
Advancing a New Era of CNS Therapeutics
Utilizing our unique di si-RNA platform, Atalanta Therapeutics is dedicated to finding solutions for intractable diseases of the central nervous system. Our pipeline is composed of programs addressing diseases with significant unmet need with the potential to improve the lives of millions of patients around the world.
Epilepsy
KCNT1 (ATL-201)
Genetic Epilepsy
KCNT1 (ATL-201) progress: 55%
Huntington’s Disease
Pan HTT (ATL-101)
Huntington’s Disease
Pan HTT (ATL-101) progress: 50%
MSH3
Huntington’s Disease
MSH3 progress: 25%
Pain
NAV 1.7 (ATL-301)
Multiple Indications
NAV 1.7 (ATL-301) progress: 30%
Alzheimer’s Disease
APOE
Alzheimer’s Disease
APOE progress: 25%
CD33
Alzheimer’s Disease
CD33 progress: 25%
CNS Disorders
Undisclosed
Multiple Targets
Undisclosed progress: 25%


CNS Disorders
Undisclosed
Multiple Targets
Undisclosed progress: 35%

